Cost-effectiveness of insulin aspart versus human soluble insulin in type 2 diabetes in four European countries: subgroup analyses from the PREDICTIVE study

References

• Bjork S. The cost of diabetes and diabetes care. Diabetes Res Clin Pract 2001;54(Suppl 1):S13–18
   PubMedGoogle Scholar
• Vora JP, Ibrahim HA, Bakris GL. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 2000;14:667–85
   Google Scholar
• Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S5–12
   PubMed Web of Science ®Google Scholar
• The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86
   PubMed Web of Science ®Google Scholar
• The UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53
   PubMed Web of Science ®Google Scholar
• Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE – a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabetes Obes Metab 2007;9:428–34
   PubMed Web of Science ®Google Scholar
• Eldor R, Stern E, Milicevic Z, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract 2005;68:30–5
   Web of Science ®Google Scholar
• Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999;42:1151–67
   PubMed Web of Science ®Google Scholar
• Barnett AH, Owens DR. Insulin analogues. Lancet 1997;349:47–51
   PubMed Web of Science ®Google Scholar
• Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193–201
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin 2004;20:5–26
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27–40
   PubMed Web of Science ®Google Scholar
• Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002;45:S23–8
   Google Scholar
• Eliasson B, Cederholm J, Nilsson P, Gudbjornsdottir S. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996–2003. Diabet Med 2005;22:1420–6
   PubMed Web of Science ®Google Scholar
• Henriksson F, Agardh CD, Berne C, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248:387–96
   PubMed Web of Science ®Google Scholar
• Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of type II diabetes. Diabetologia 2002;45:S13–17
   PubMed Web of Science ®Google Scholar
• Lahoz-Rallo B, Blanco-Gonzalez M, Casas-Ciria I, et al. Cardiovascular disease risk in subjects with type 2 diabetes mellitus in a population in southern Spain. Diabetes Res Clin Pract 2007;76:436–44
   PubMed Web of Science ®Google Scholar
• Lopez IM, Diez A, Velilla S, et al. Prevalence of diabetic retinopathy and eye care in a rural area of Spain. Ophthalmic Epidemiol 2002;9:205–14
   PubMed Web of Science ®Google Scholar
• Arteagoitia JM, Larranaga MI, Rodriguez JL, et al. Incidence, prevalence and coronary heart disease risk level in known type 2 diabetes: a sentinel practice network study in the Basque Country, Spain. Diabetologia 2003;46:899–909
   PubMed Web of Science ®Google Scholar
• Colivicchi F, Uguccioni M, Ragonese M, et al. Cardiovascular risk factor control among diabetic patients attending community-based diabetic care clinics in Italy. Diabetes Res Clin Pract 2007;75:176–83
   PubMed Web of Science ®Google Scholar
• The prevalence of coronary heart disease in type 2 diabetic patients in Italy: the DAI study. Diabet Med 2004;21:738–45
   PubMed Web of Science ®Google Scholar
• Pantoflinski J, Kieltyka A, Szybinski Z. [Visual disability due to diabetes in Cracow voivodeship]. Pol Arch Med Wewn 2001;106:847–51
   Google Scholar
• Kinalska I., Niewada M, Glogowski C, et al. Cost of diabetes type 2 in Poland (CODIP). Diabetologia Praktyczna 2004;5:1–8
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decisionmaking. Curr Med Res Opin 2004;20:5–26
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006;22:1523–34
   PubMed Web of Science ®Google Scholar
• Läkemedelsförmänsnämnden (Pharmaceutical Benefits Board of Sweden). LFN,2006. Available at: http://www.lfn.se/ [Last accessed 11 January 2004]
   Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327–40
   Google Scholar
• Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776–81
   PubMed Web of Science ®Google Scholar
• Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269–74
   PubMed Web of Science ®Google Scholar
• Weinstein MC, O’Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in healthcare evaluation: report of the ISPOR Task Force on Good Research Practices – Modeling Studies. Value Health 2003;6: 9–17
   PubMed Web of Science ®Google Scholar
• Södra Regionvardsnämnden. Universitetssjukhusen Lund och Malmö. Universitetssjukhusen Lund och Malmö 2006. Available at: http://www.srvn.org/ [Last accessed 11 January 2006]
   Google Scholar
• The Swedish Association of Local Authorities and Regions (SALAR). Svenska Kommunföorbundet och Landstingsfördundet i Samverkan. The Swedish Association of Local Authorities and Regions (SALAR) 2006. Available at: http://sas.lf.se/ [Last accessed 11 January 2006]
   Google Scholar
• Henriksson F. Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics 2002;20(Suppl 1):43–53
   PubMedGoogle Scholar
• Ghatnekar O, Persson U, Willis M, Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:767–78
   PubMed Web of Science ®Google Scholar
• Institute de Salud Carlos III. Analisis coste-efectividad de diferentes estrategias para el cribado y tratamiento de la retinopatia diabetica en pacientes con diabetes mellitus. Min de Sanidad Consumo 2004;00/10116
   Google Scholar
• SOIKOS. Centre d’Estudis En Economia De La Salut I De La Politica Social SL (SOIKOS). Base de Datos de Costes Sanitarios, Spain. 2004. Available at: www.soikos.com
   Google Scholar
• Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmaco-economics 2003;21:651–9
   Google Scholar
• Oliva J, Lobo F, Molina B, Monereo S. Direct healthcare costs of diabetes mellitus patients in Spain. Diabetes Care 2004;27:2616–21
   PubMed Web of Science ®Google Scholar
• Aros F. Guias de actuacion clinica de la Sociedad Espanola de Cardiologia en el infarto agudo de miocardio. Rev Esp Cardiol 1999;52:919–56
   PubMedGoogle Scholar
• Mullins CD, Sikirica M, Seneviratne V, et al. Comparisons of hypertension-related costs from multinational clinical studies. Pharmacoeconomics 2004;22:1001–14
   PubMed Web of Science ®Google Scholar
• Bastida J, Aguilar S, Alvarez M, Gonzalez D. The Economic Burden of Stroke in Spain. Value in Health 2003;6:614
   Web of Science ®Google Scholar
• Real Decreto 1247/2002 de 3 de diciembre por el que se regula la gestion del fondo de cohesion sanitaria. BOE numero 290 ed. 2004.
   Google Scholar
• Lamas J, Alonso M, Saavadra J, et al. Costes de la dialisis cronica en un hospital publicoL mitos y realidades. Nefrologia 2002;22:269–76
   PubMedGoogle Scholar
• Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: a Spanish perspective. Nefrologia 2004;24:231–8
   PubMed Web of Science ®Google Scholar
• Castells X, Alonso J, Castilla M, et al. Outcomes and costs of outpatient and inpatient cataract surgery: a randomised clinical trial. J Clin Epidemiol 2001;54:23–9
   PubMed Web of Science ®Google Scholar
• Calle-Pascual AL, Redondo MJ, Ballesteros M, et al. Nontraumatic lower extremity amputations in diabetic and non-diabetic subjects in Madrid, Spain. Diabetes Metab 1997;23:519–23
   Google Scholar
• Porta M, Rizzitiello A, Tomalino M, et al. Comparison of the cost-effectiveness of three approaches to screening for and treating sight-threatening diabetic retinopathy. Diabetes Metab 1999;25:44–53
   PubMed Web of Science ®Google Scholar
• Lucioni C, Mazzi S, Neeser K. Analisi di costo-efficacia della terapia combinata con pioglitazone nel trattamento del diabete mellito di tipo 2 in Italia. Pharmacoeconomics 2004;6: 81–93
   Google Scholar
• Ministero della Sanita. Aggiornamento delle tariffe delle prestazioni di assistenza ospedaliera di cui al DecretoMinisteriale 12 dicembre 1994. Ministero della Sanita 1997;Suppl ord. alla G.U.
   Google Scholar
• Rudelli G, Annemans L, Spiesser J, et al. An economic evaluation of clopidigrel vs aspirin in secondaryprevention of ischemic events in high risk atherothrombotic patients in Italy. 2004
   Google Scholar
• Palmer AJ, Annemans L, Roze S, et al. Cost-effectiveness analysis of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: the Italian perspective. PharmacoEconomics – Italian Research Articles 2004;7:41–55
   Google Scholar
• The DCCT Research Group. Resource utilization and costs of care in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:1468–78
   PubMed Web of Science ®Google Scholar
• Ministero della Sanita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio Sanitorio Nazionale e relative tariffe. Decreto Ministeriale 22 luglio 1996. Decreto Ministeriale 2004;216
   Google Scholar
• OEMF. Informatorie Farmaceutico (marzo 2003) (Aggiornamento). Milano, 2004
   Google Scholar
• Legge 18/1980. Indennita di accompagnamento agli invalidi civili totalmente inabili. Pubblicata su G.U. n. 44 ed. 1980
   Google Scholar
• Kawalek P, Pilc A. Introduction to the pharmacoeconomics of diabetes care. Diabetol Pol 2003;10:429–33
   Google Scholar
• Kawalec P, Sadowski R, Pilc A. Costs of the treatment of ischaemic heart disease in type 1 and type 2 diabetes mellitus patients in Poland. Diabetol Pol 2004;11: 125–30
   Google Scholar
• Kawalek P, Pilc A. Costs of diabetic nephropathy in Poland. Diabetol Pol 2003;10:398–405
   Google Scholar
• Kawalek P, Pilc A. Costs of diabetic foot in Poland. Medycyna Metaboliczna 2003;7:11–7
   Google Scholar
• Kawalek P, Lis J, Pilc A. Costs of diabetic ischemia of lower extremities in Poland. Standardy Medyczne 2004;6:718–24
   Google Scholar
• Kawalek P, Pilc A. Cost of diabetic retinopathy in Poland. Okulistyka 2003;(3):52–8
   Google Scholar